Literature DB >> 10471598

Respiratory syncytial and other virus infections in persons with chronic cardiopulmonary disease.

E E Walsh1, A R Falsey, P A Hennessey.   

Abstract

Respiratory syncytial virus (RSV) has been increasingly recognized as an important cause of serious respiratory illness in some adult populations, including those with underlying cardiopulmonary diseases. However, the precise incidence and the clinical impact of RSV in this group are unknown. Therefore, the incidence and clinical impact of RSV infection in persons with chronic obstructive pulmonary disease (COPD) and congestive heart failure (CHF) who reside in the community were prospectively evaluated over two consecutive winters in 134 persons. Eight RSV (incidence of 4.3 per 100 subject-winters), 13 influenza A (incidence of 7.0 per 100 subject-winters), seven rhinovirus, nine coronavirus, and two parainfluenza virus infections were identified. The clinical illnesses associated with RSV and influenza A virus were similar, causing both upper and lower respiratory signs and symptoms. The clinical impact was significant as three of eight RSV-infected subjects were hospitalized compared with six of 13 influenza A-infected persons and zero of seven rhinovirus-infected persons.

Entities:  

Mesh:

Year:  1999        PMID: 10471598     DOI: 10.1164/ajrccm.160.3.9901004

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  55 in total

1.  Effects of aging on the adaptive immune response to respiratory virus infections.

Authors:  Ross B Fulton; Steven M Varga
Journal:  Aging health       Date:  2009-12-01

2.  Respiratory viruses augment the adhesion of bacterial pathogens to respiratory epithelium in a viral species- and cell type-dependent manner.

Authors:  Vasanthi Avadhanula; Carina A Rodriguez; John P Devincenzo; Yan Wang; Richard J Webby; Glen C Ulett; Elisabeth E Adderson
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

3.  Murine immune responses to virus-like particle-associated pre- and postfusion forms of the respiratory syncytial virus F protein.

Authors:  Lori McGinnes Cullen; Madelyn R Schmidt; Sarah A Kenward; Robert T Woodland; Trudy G Morrison
Journal:  J Virol       Date:  2015-04-22       Impact factor: 5.103

4.  Protective efficacy and immunogenicity of an adenoviral vector vaccine encoding the codon-optimized F protein of respiratory syncytial virus.

Authors:  Rebekka Kohlmann; Sarah Schwannecke; Bettina Tippler; Nicola Ternette; Vladimir V Temchura; Matthias Tenbusch; Klaus Uberla; Thomas Grunwald
Journal:  J Virol       Date:  2009-09-23       Impact factor: 5.103

5.  Diagnosis of respiratory syncytial virus infection: comparison of reverse transcription-PCR to viral culture and serology in adults with respiratory illness.

Authors:  Ann R Falsey; Maria A Formica; Edward E Walsh
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

6.  Multiple cis regulatory elements control RANTES promoter activity in alveolar epithelial cells infected with respiratory syncytial virus.

Authors:  A Casola; R P Garofalo; H Haeberle; T F Elliott; R Lin; M Jamaluddin; A R Brasier
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

7.  Respiratory syncytial virus infection in older adults: an under-recognized problem.

Authors:  Angela R Branche; Ann R Falsey
Journal:  Drugs Aging       Date:  2015-04       Impact factor: 3.923

8.  Respiratory syncytial virus vaccine: Is it coming?

Authors:  Valérie Sales; Elaine El Wang
Journal:  Paediatr Child Health       Date:  2003-12       Impact factor: 2.253

Review 9.  Current research on respiratory viral infections: Fourth International Symposium.

Authors:  Michael G Ison; John Mills; Peter Openshaw; Maria Zambon; Albert Osterhaus; Frederick Hayden
Journal:  Antiviral Res       Date:  2002-08       Impact factor: 5.970

10.  Modification of the respiratory syncytial virus f protein in virus-like particles impacts generation of B cell memory.

Authors:  Madelyn R Schmidt; Lori W McGinnes-Cullen; Sarah A Kenward; Kristin N Willems; Robert T Woodland; Trudy G Morrison
Journal:  J Virol       Date:  2014-06-25       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.